About
Corporate Overview
Founders
Management
Scientific Advisory Board
Board of Directors
Board of Advisors
Partnerships
Pleadings
Videos
ACP Testimonials
CEO Updates
News
Technology
Technology Overview
Manufacturing
Intellectual Property
Publications
Clinical Pipeline
ACP-01 Phase II Clinical Trial for CLI
CLI Phase II Trial Summary
Platform
Critical Limb Ischemia
Investors
Investor Overview
A Three Minute Summary
Public Filings
AGM Materials
News & Media
News / Press Releases
Contact
MENU ≡
About
Corporate Overview
Founders
Management
Scientific Advisory Board
Board of Directors
Board of Advisors
Partnerships
Pleadings
Videos
ACP Testimonials
CEO Updates
News
Technology
Technology Overview
Manufacturing
Intellectual Property
Publications
Clinical Pipeline
ACP-01 Phase II Clinical Trial for CLI
CLI Phase II Trial Summary
Platform
Critical Limb Ischemia
Investors
Investor Overview
A Three Minute Summary
Public Filings
AGM Materials
News & Media
News / Press Releases
Contact
News & Media
all
2020
2019
2018
2017
2016
2015
2014
Nov 23
/ 2018
MANAGEMENT’S DISCUSSION AND ANALYSIS
Nov 23
/ 2018
Interim Condensed Consolidated Financial Statements
Nov 09
/ 2018
Hemostemix Announces Development of an ACP-01 Allogeneic Process and Initiation of R&D for Autologous NCP-01 Neural Cellular Precursors
Nov 08
/ 2018
Hemostemix Announces Important Manufacturing Process Refinements
Oct 30
/ 2018
Hemostemix Announces OTCQB Listing and DTC Eligibility
Oct 09
/ 2018
Hemostemix Announces Three Additional Sites Enrolled in Phase II Clinical Trial
Sep 27
/ 2018
Hemostemix Announces Voting Results of the Annual and Special Meeting of Shareholders
Sep 24
/ 2018
Hemostemix Announces Addition to Its Clinical Trial Management Team
Aug 24
/ 2018
Interim Condensed Consolidated Financial Statements
Aug 24
/ 2018
Management’s Discussion and Analysis
Aug 16
/ 2018
Hemostemix Announces Two New Strategic Trial Sites in Texas
Jul 18
/ 2018
Hemostemix Announces First U.S. Patients Treated in Phase II Clinical Trial
Jul 05
/ 2018
Hemostemix Formalizes World-Class Scientific Advisory Board
May 30
/ 2018
Major Milestone Achieved With First 3 U.S. Trial Sites
May 28
/ 2018
Management’s Discussion and Analysis
May 28
/ 2018
Interim Condensed Consolidated Financial Statements
May 23
/ 2018
Hemostemix Announces New EU Patent Grant
May 03
/ 2018
Hemostemix Announces First Patient Treated in Phase II Clinical Trial
May 01
/ 2018
MANAGEMENT’S DISCUSSION AND ANALYSIS
May 01
/ 2018
Hemostemix Publishes 2017 Financials
Apr 27
/ 2018
Hemostemix Announces Trial Site for Phase II Clinical Trial
Apr 19
/ 2018
Hemostemix Announces US FDA Clinical Trial Approval
Feb 23
/ 2018
Hemostemix Signs License Agreement with Aspire Health Science
Feb 22
/ 2018
Hemostemix Signs Manufacturing Agreement with Aspire Health Science